Cantargia acquires Cellerant IP on IL1RAP
Cantargia AB today announced the acquisition of a patent portfolio from Cellerant Therapeutics Inc covering aspects around the interleukin 1 receptor accessory protein (IL1RAP). The acquired IP includes a US patent on IL1RAP as a target for antibody therapy in leukemia. Thereby, Cantargia has broadened its IP portfolio and secured ownership of the key patents around IL1RAP as a target for cancer therapy.Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). In the most advanced program, the antibody CAN04 binds IL1RAP with high